A prevalence study of primary dystonia in eight Europe

Journal of Neurology 247, 787-792 DOI: 10.1007/s004150070094

Citation Report

#	Article	IF	CITATIONS
1	Dystonia: an update on genetics and treatment. Current Opinion in Neurology, 2001, 14, 471-475.	1.8	8
3	Blepharospasm. Neurology, 2002, 59, 1306-1312.	1.5	139
4	Service-Based Survey of Dystonia in Munich. Neuroepidemiology, 2002, 21, 202-206.	1.1	90
5	The genetics of primary dystonias and related disorders. Brain, 2002, 125, 695-721.	3.7	175
6	The prevalence of primary dystonia in the general community. Neurology, 2002, 59, 941-943.	1.5	126
7	Classification and genetics of dystonia. Lancet Neurology, The, 2002, 1, 316-325.	4.9	142
8	Epidemiology of primary blepharospasm. Movement Disorders, 2002, 17, 7-12.	2.2	77
9	Secondary cervical dystonia associated with structural lesions of the central nervous system. Movement Disorders, 2003, 18, 60-69.	2.2	191
10	Slowly progressive cerebellar ataxia and cervical dystonia: Clinical presentation of a new form of spinocerebellar ataxia?. Movement Disorders, 2003, 18, 200-206.	2.2	35
11	Epidemiology of primary dystonias in Japan: Comparison with Western countries. Movement Disorders, 2003, 18, 1196-1198.	2.2	60
12	VIM thalamic stimulation for tremor in a patient with IgM paraproteinaemic demyelinating neuropathy. Movement Disorders, 2003, 18, 1192-1195.	2.2	36
13	Periodic alternating nystagmus and rebound nystagmus in spinocerebellar ataxia type 6. Movement Disorders, 2003, 18, 1201-1204.	2.2	29
14	Brainstem myoclonus in generalised tetanus. Movement Disorders, 2003, 18, 1204-1206.	2.2	8
15	Severe generalized dystonia as a presentation of a patient withaprataxin gene mutation. Movement Disorders, 2003, 18, 1198-1200.	2.2	27
16	Pilot study of effect of emotional stimuli on tic severity in children with Tourette's syndrome. Movement Disorders, 2003, 18, 1392-1395.	2.2	46
17	Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Movement Disorders, 2003, 18, 1190-1192.	2.2	28
18	Prevalence of primary late-onset focal dystonia in the Belgrade population. Movement Disorders, 2003, 18, 1389-1392.	2.2	47
19	Positron emission tomography scanning in essential blepharospasm. American Journal of Ophthalmology, 2003, 136, 846-852.	1.7	61

TATION REDO

#	ARTICLE	IF	Citations
20	Trastornos del movimiento. Concepto, epidemiologÃa y clasificaciÃ ³ n. Medicine, 2003, 8, 5075-5080.	0.0	0
21	Equal use of heath services does not mean equal care for stroke victims of low socioeconomic status. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 267-267.	0.9	0
22	Does sex influence age at onset in cranial-cervical and upper limb dystonia?. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 265-267.	0.9	11
23	Agreement among neurologists on the clinical diagnosis of dystonia at different body sites. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 348-350.	0.9	53
24	Prevalence of primary focal and segmental dystonia in Oslo. Neurology, 2003, 61, 1294-1296.	1.5	80
25	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. , 2003, , CD004314.		9
26	Pain in Cervical Dystonia. Pain and Headache, 2003, 14, 54-70.	0.1	3
29	Deep brain stimulation for dystonia. Expert Review of Medical Devices, 2004, 1, 33-41.	1.4	61
30	Capturing the true burden of dystonia on patients. Neurology, 2004, 63, 1629-1633.	1.5	94
31	Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 749-753.	0.9	119
32	Botulinum toxin type B for cervical dystonia. , 2004, , CD004315.		16
33	Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. European Journal of Neurology, 2004, 11, 361-370.	1.7	127
34	Epidemiology of primary dystonia. Lancet Neurology, The, 2004, 3, 673-678.	4.9	213
35	Cervical dystonia as first manifestation of multiple sclerosis. Journal of Neurology, 2004, 251, 1408-1410.	1.8	20
36	Botulinum toxin treatment of occupational and focal hand dystonia. Movement Disorders, 2004, 19, S116-S119.	2.2	50
37	Patient-based outcomes of cervical dystonia: A review of rating scales. Movement Disorders, 2004, 19, 1054-1059.	2.2	38
38	Fracture of the odontoid process complicating tardive dystonia. Movement Disorders, 2004, 19, 983-985.	2.2	14
39	Does training improve writer's cramp?. Journal of Hand Therapy, 2004, 17, 349-363.	0.7	54

ARTICLE IF CITATIONS # Benign Essential Blepharospasm: Risk Factors with Reference to Hemifacial Spasm. Journal of 40 0.4 17 Neuro-Ophthalmology, 2005, 25, 280-285. Botulinum toxin type A therapy for cervical dystonia. The Cochrane Library, 2005, , CD003633. 1.5 Botulinum toxin type A versus anticholinergics for cervical dystonia. The Cochrane Library, 2005, , 42 1.5 16 CD004312. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive 54 cervical dystonia. Movement Disorders, 2005, 20, 1152-1160. A new screening tool for cervical dystonia. Neurology, 2005, 64, 2046-2049. 44 1.5 15 Dystonia. Clinics in Geriatric Medicine, 2006, 22, 899-914. 1.0 Functional magnetic resonance imaging study of writer \hat{E}^{1} /4s cramp. Chinese Medical Journal, 2006, 119, 0.9 46 37 1263-1271. A 9-year review of dystonia from a movement disorders clinic in Singapore. European Journal of 1.7 Neurology, 2006, 13, 77-81. 49 Botulinum toxin therapy of writer's cramp. European Journal of Neurology, 2006, 13, 55-59. 1.7 47 Prevalence study of primary dystonia in Iceland. Movement Disorders, 2006, 21, 293-298. 2.2 Prevalence of dystonia in Akita prefecture in Northern Japan. Movement Disorders, 2006, 21, 1047-1049. 51 2.2 20 Analysis of blink rate in patients with blepharospasm. Movement Disorders, 2006, 21, 1225-1229. 2.2 Epidemiology of primary focal dystonias in the western area of tottori prefecture in Japan: 53 2.2 28 Comparison with prevalence evaluated in 1993. Movement Disorders, 2006, 21, 1503-1506. Prevalence of primary blepharospasm in Sardinia, Italy: A service-based survey. Movement Disorders, 54 2.2 2006, 21, 2005-2008 Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in 55 2.2 60 idiopathic Parkinson's disease. Movement Disorders, 2006, 21, 2008-2010. Focal hand dystonia. Practical Neurology, 2006, 6, 278-287. Epidemiology of Primary and Secondary Dystonia. Medical Psychiatry, 2006, , 11-20. 57 0.2 0 Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. 108 Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 264-270.

#	Article	IF	CITATIONS
59	Shedding Light on Blepharospasm: A Patient–Researcher Partnership Approach to Assessment of Photophobia and Impact on Activities of Daily Living. Neuro-Ophthalmology, 2007, 31, 49-54.	0.4	10
60	Clinical Diagnosis and Management of Dystonia. , 0, , .		7
61	Symptomatic autoregulatory failure in acute ischemic stroke. Neurology, 2007, 68, 389-390.	1.5	16
62	Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology, 2007, 68, 387-388.	1.5	45
63	Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology, 2007, 69, 676-680.	1.5	51
64	Primary craniocervical dystonia presenting as a respiratory emergency. Neurology, 2007, 68, 388-389.	1.5	4
65	Deep brain stimulation in childhood: an effective treatment for early onset idiopathic generalised dystonia. Archives of Disease in Childhood, 2007, 92, 708-711.	1.0	53
67	Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma. World Neurosurgery, 2007, 68, 665-670.	1.3	6
68	Clinical profile of various sub-types of writer's cramp. Parkinsonism and Related Disorders, 2007, 13, 421-424.	1.1	18
69	Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism and Related Disorders, 2007, 13, 411-416.	1.1	83
70	The management of cervical dystonia. Expert Opinion on Pharmacotherapy, 2007, 8, 129-140.	0.9	23
71	Aspectos terapéuticos actuales de la toxina botulÃnica en neurologÃa. EMC - Kinesiterapia - Medicina FAsica, 2007, 28, 1-14.	0.1	0
73	Dystonias. , 2007, , 1-5.		0
74	First determination of the incidence of the uniqueTOR1A gene mutation, c.907delGAG, in a Mediterranean population. Movement Disorders, 2007, 22, 884-888.	2.2	35
75	Refinement of the DYT15 locus in myoclonus dystonia. Movement Disorders, 2007, 22, 888-892.	2.2	41
76	Community survey of primary dystonia in the city of Kolkata, India. Movement Disorders, 2007, 22, 2031-2036.	2.2	31
77	Excessive blinking as an initial manifestation of juvenile Huntington's disease. Neurological Sciences, 2008, 29, 275-277.	0.9	20
78	Taskâ€specific Dystonias. Annals of the New York Academy of Sciences, 2008, 1142, 179-199.	1.8	147

# 79	ARTICLE Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. Parkinsonism and Related Disorders, 2008, 14, 407-414.	IF 1.1	CITATIONS 82
80	Epidemiology , clinical presentation , and diagnosis of cervical dystonia. Neurologic Clinics, 2008, 26, 23-42.	0.8	51
81	Selective denervation of the levator scapulae muscle: an amendment to the Bertrand procedure for the treatment of spasmodic torticollis. Journal of Neurosurgery, 2008, 108, 757-763.	0.9	15
82	GENETICS OF DYSTONIA. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 65-89.	0.4	3
83	Botulinum Neurotoxin Treatment of Limb and Occupational Dystonias. , 2009, , 102-111.		0
84	Prevalence of Primary Focal or Segmental Dystonia in Adults in the District of Foggia, Southern Italy: A Service-Based Study. Neuroepidemiology, 2009, 33, 117-123.	1.1	16
85	Handbook of Movement Disorders. , 2009, , .		2
86	Impact of dystonia on quality of life and health in a Swedish population. Acta Neurologica Scandinavica, 2009, 119, 376-382.	1.0	29
87	Movement disorders associated with complex regional pain syndrome in children. Developmental Medicine and Child Neurology, 2009, 51, 557-562.	1.1	23
89	Quality of life in patients with focal dystonia. Clinical Neurology and Neurosurgery, 2009, 111, 161-164.	0.6	104
90	Meige syndrome: What's in a name?. Parkinsonism and Related Disorders, 2009, 15, 483-489.	1.1	64
91	Cervical dystonia. Future Neurology, 2009, 4, 639-647.	0.9	0
93	Treatment of focal hand dystonia. , 0, , 61-76.		1
95	Bilateral pallidal stimulation in children and adolescents with primary generalized dystonia – Report of six patients and literature-based analysis of predictive outcomes variables. Brain and Development, 2010, 32, 223-228.	0.6	77
97	Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia. Movement Disorders, 2010, 25, 2183-2187.	2.2	27
98	The epidemiology of primary dystonia: current evidence and perspectives. European Journal of Neurology, 2010, 17, 9-14.	1.7	73
99	Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. European Journal of Neurology, 2010, 17, 94-108.	1.7	50
100	Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye, 2010, 24, 600-607.	1.1	61

		ON REPORT	
#	Article	IF	Citations
101	Scenes in movement. Movement disorders on film. NeurologÃa (English Edition), 2010, 25, 108-115.	0.2	0
102	Working capacity and cervical dystonia. Parkinsonism and Related Disorders, 2010, 16, 215-217.	1.1	21
104	Therapeutic Challenges in Dystonia. Neurologic Clinics, 2010, 28, 927-940.	0.8	7
105	Structural, functional and molecular imaging of the brain in primary focal dystonia—A review. NeuroImage, 2011, 56, 1011-1020.	2.1	132
106	Botulinum Toxin A (Dysport®). Drugs, 2011, 71, 1043-1058.	4.9	15
108	Quantifying muscle asymmetries in cervical dystonia with electrical impedance: A preliminary assessment. Clinical Neurophysiology, 2011, 122, 1027-1031.	0.7	13
109	Prevalence and diagnostic challenge of dystonia in Thailand: A service-based study in a tertiary university referral centre. Parkinsonism and Related Disorders, 2011, 17, S15-S19.	1.1	12
110	Secondary dystonia in a Botulinum Toxin Clinic: Clinical characteristics, neuroanatomical substrate and comparison with idiopathic dystonia. Parkinsonism and Related Disorders, 2011, 17, 749-752.	1.1	9
111	Adult-onset dystonia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 481-511.	1.0	37
112	Dystonic syndromes. , 0, , 121-130.		1
113	A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatric Disease and Treatment, 2012, 8, 13.	1.0	9
114	Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey. Canadian Journal of Neurological Sciences, 2011, 38, 704-711.	0.3	32
115	Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies. Clinical Investigation, 2011, 1, 891-900.	0.0	4
116	Genetic and clinical features of primary torsion dystonia. Neurobiology of Disease, 2011, 42, 127-135.	2.1	75
117	Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurology, The, 2011, 10, 1074-1085.	4.9	178
118	Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. Journal of Neural Transmission, 2011, 118, 233-239.	1.4	78
119	Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trial. Movement Disorders, 2011, 26, 1521-1528.	2.2	73
120	Milestones in dystonia. Movement Disorders, 2011, 26, 1106-1126.	2.2	56

	CHATION	REPORT	
#	Article	IF	CITATIONS
121	A clinical test for the alcohol sensitivity of essential tremor. Movement Disorders, 2011, 26, 2291-2295.	2.2	24
122	An unusual neurological syndrome of crawling gait, dystonia, pyramidal signs, and limited speech. Movement Disorders, 2011, 26, 2279-2283.	2.2	3
123	Projected numbers of people with movement disorders in the years 2030 and 2050. Movement Disorders, 2011, 26, 2286-2290.	2.2	127
124	Association of <i>SNCA</i> with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders, 2011, 26, 2283-2286.	2.2	21
125	Genetics of Dystonia. Seminars in Neurology, 2011, 31, 441-448.	0.5	27
126	Yazıcı Krampının A Tipi Botulinum Toksini ile Tedavisi. Noropsikiyatri Arsivi, 2011, 48, 1-1.	0.7	0
127	Early-onset primary dystonia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 465-479.	1.0	4
128	Surgical Treatment of Dystonia. International Review of Neurobiology, 2011, 98, 573-589.	0.9	14
129	Evaluation of the quality of life in patients with segmental dystonia. Vojnosanitetski Pregled, 2012, 69, 759-764.	0.1	8
130	Botulinum Toksini Tedavisi Almış 118 Servikal Distonili Olgunun Retrospektif Değerlendirmesi. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2012, 18, 104-107.	0.1	0
131	Phenotypes and genetic architecture of focal primary torsion dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1006-1011.	0.9	22
132	Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. Journal of Neurology, 2012, 259, 2519-2526.	1.8	50
133	The prevalence of primary dystonia: A systematic review and metaâ€analysis. Movement Disorders, 2012, 27, 1789-1796.	2.2	272
134	Diagnosis of Primary Task-Specific Lower Extremity Dystonia in a Runner. Journal of Orthopaedic and Sports Physical Therapy, 2012, 42, 688-697.	1.7	12
135	A Comparison of Facial Muscle Squeezing versus Non-facial Muscle Squeezing on the Efficacy of BotulinumToxin-A Injections for the Treatment of Facial Dystonia. Orbit, 2012, 31, 400-403.	0.5	2
136	Common polymorphisms in dystonia-linked genes and susceptibility to the sporadic primary dystonias. Parkinsonism and Related Disorders, 2012, 18, 351-357.	1.1	20
137	The Toronto Western Spasmodic Torticollis Rating Scale: Reliability in neurologists and physiotherapists. Parkinsonism and Related Disorders, 2012, 18, 635-637.	1.1	23
138	Muscle selection for treatment of cervical dystonia with botulinum toxin – A systematic review. Parkinsonism and Related Disorders, 2012, 18, 731-736.	1.1	31

#	Article	IF	CITATIONS
139	Diagnosis of dystonic syndromes—a new eight-question approach. Nature Reviews Neurology, 2012, 8, 275-283.	4.9	13
140	Mutations in ANO3 Cause Dominant Craniocervical Dystonia: Ion Channel Implicated in Pathogenesis. American Journal of Human Genetics, 2012, 91, 1041-1050.	2.6	224
141	Therapeutic Use of Botulinum Toxin in Neurorehabilitation. Journal of Toxicology, 2012, 2012, 1-12.	1.4	30
142	Self-Perceived non-motor aspects of cervical dystonia and their association with disability. Journal of Rehabilitation Medicine, 2012, 44, 950-954.	0.8	24
143	Dystonia Arising from Occupations: The Clinical Phenomenology and Therapy. , 2012, , .		2
144	10.5 Therapie der Dystonie. , 2012, , .		0
146	"Visual sensory trick―in patient with cervical dystonia. Neurological Sciences, 2012, 33, 665-667.	0.9	8
148	Cervical dystonia: effectiveness of a standardized physical therapy program; study design and protocol of a single blind randomized controlled trial. BMC Neurology, 2013, 13, 85.	0.8	18
149	Genetics in Dystonia: An Update. Current Neurology and Neuroscience Reports, 2013, 13, 410.	2.0	13
150	Rehabilitación de las distonÃas. EMC - Kinesiterapia - Medicina FÃsica, 2013, 34, 1-20.	0.1	1
151	Cervical dystonia: Improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism and Related Disorders, 2013, 19, 533-538.	1.1	19
153	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	2.2	1,754
154	Anxiety and depression in primary and secondary dystonia: A burden on health related quality of life. Neurology Psychiatry and Brain Research, 2013, 19, 80-85.	2.0	9
155	Genetic Issues in the Diagnosis of Dystonias. Frontiers in Neurology, 2013, 4, 34.	1.1	27
156	Active exercise for individuals with cervical dystonia: a pilot randomized controlled trial. Clinical Rehabilitation, 2013, 27, 226-235.	1.0	38
158	The sodium leak channel, NALCN, in health and disease. Frontiers in Cellular Neuroscience, 2014, 8, 132.	1.8	116
159	Temporal discrimination, a cervical dystonia endophenotype: Penetrance and functional correlates. Movement Disorders, 2014, 29, 804-811.	2.2	70
160	Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. Movement Disorders, 2014, 29, 245-251.	2.2	43

#	Article	IF	CITATIONS
161	Neuropathological features of genetically confirmed DYT1 dystonia: investigating disease-specific inclusions. Acta Neuropathologica Communications, 2014, 2, 159.	2.4	21
162	Quality of life in patients with craniocervical dystonia: Italian validation of the "Cervical Dystonia Impact Profile (CDIP-58)―and the "Craniocervical Dystonia Questionnaire (CDQ-24)― Neurological Sciences, 2014, 35, 1053-1058.	0.9	3
163	The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. Journal of Neurology, 2014, 261, 1857-1865.	1.8	70
164	Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurology, The, 2014, 13, 875-884.	4.9	281
165	Bladder function in patients with dystonia undergoing deep brain stimulation. Parkinsonism and Related Disorders, 2014, 20, 1015-1017.	1.1	21
166	EMG coherence and spectral analysis in cervical dystonia: Discriminative tools to identify dystonic muscles?. Journal of the Neurological Sciences, 2014, 347, 167-173.	0.3	17
167	Anterocollis and anterocaput. Clinical Neurology and Neurosurgery, 2014, 127, 44-53.	0.6	8
168	Neurosurgical treatment for dystonia: Long-term outcome in a case series of 80 patients. Clinical Neurology and Neurosurgery, 2014, 123, 191-198.	0.6	14
169	Treatment of focal hand dystonia. , 0, , 71-84.		1
170	We Are Able, We Intend, We Act—But We Do Not Succeed: A Theoretical Framework for a Better Understanding of Paradoxical Performance in Sports. Journal of Clinical Sport Psychology, 2014, 8, 357-377.	0.6	23
171	Lack of validation of variants associated with cervical dystonia risk: A GWAS replication study. Movement Disorders, 2014, 29, 1825-1828.	2.2	15
172	A retrospective study to assess resource utilization in patients with cervical dystonia in the United Kingdom. Neuropsychiatric Disease and Treatment, 2015, 11, 647.	1.0	3
173	AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis. ClinicoEconomics and Outcomes Research, 2015, 7, 441.	0.7	6
174	Dystoniaâ~†. , 2015, , .		0
175	Task-Specific Dystonia in Professional Musicians. Deutsches Ärzteblatt International, 2015, 112, 871-7.	0.6	19
177	Exploring factors related to physical activity in cervical dystonia. BMC Neurology, 2015, 15, 247.	0.8	10
178	Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial. Parkinsonism and Related Disorders, 2015, 21, 976-980.	1.1	24
179	Effectiveness of selective peripheral denervation in combination with pallidal deep brain stimulation for the treatment of cervical dystonia. Acta Neurochirurgica, 2015, 157, 435-442.	0.9	9

#	Article	IF	CITATIONS
180	Postoperative MRI localisation of electrodes and clinical efficacy of pallidal deep brain stimulation in cervical dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 833-839.	0.9	35
181	Dystonia and Dystonic Syndromes. , 2015, , .		3
183	A Clinical Profile of 125 Patients with Writer's Cramp. European Neurology, 2015, 73, 316-320.	0.6	13
184	Management of Benign Essential Blepharospasm. , 2015, , 443-456.		0
185	The X-Linked Hypothesis of Brain Disorders. Neuroscientist, 2015, 21, 589-598.	2.6	1
186	TOR1Apolymorphisms in a Russian cohort with primary focal/segmental dystonia. International Journal of Neuroscience, 2015, 125, 671-677.	0.8	6
187	Sonographic Alteration of Basal Ganglia in Different Forms of Primary Focal Dystonia. Chinese Medical Journal, 2016, 129, 942-945.	0.9	7
188	Botulinum toxin type B for cervical dystonia. The Cochrane Library, 2016, 2016, CD004315.	1.5	36
189	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. European Journal of Neurology, 2016, 23, 772-779.	1.7	12
190	Prevalence of Dystonia in Antioquia, Colombia. Neuroepidemiology, 2016, 46, 137-143.	1.1	6
191	Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiology and Drug Safety, 2016, 25, 179-187.	0.9	68
192	High prevalence of primary focal dystonia in the Faroe Islands. Acta Neurologica Scandinavica, 2016, 133, 55-60.	1.0	21
193	Neurometabolic disorders are treatable causes of dystonia. Revue Neurologique, 2016, 172, 455-464.	0.6	8
194	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. The Cochrane Library, 2016, 2016, CD004314.	1.5	31
195	Bilateral Pallidotomy for Cervical Dystonia After Failed Selective Peripheral Denervation. World Neurosurgery, 2016, 89, 728.e1-728.e4.	0.7	15
196	Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm. Seminars in Neurology, 2016, 36, 084-091.	0.5	41
197	Delays to the diagnosis of cervical dystonia. Journal of Clinical Neuroscience, 2016, 25, 62-64.	0.8	22
198	A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. Journal of Neurology, 2016, 263, 772-780.	1.8	18

#	Article	IF	CITATIONS
199	LINCing Defective Nuclear-Cytoskeletal Coupling and DYT1 Dystonia. Cellular and Molecular Bioengineering, 2016, 9, 207-216.	1.0	18
200	A randomized trial of specialized versus standard neck physiotherapy in cervical dystonia. Parkinsonism and Related Disorders, 2016, 23, 72-79.	1.1	20
201	Late-onset primary dystonia in Zhejiang province of China: a service-based epidemiological study. Neurological Sciences, 2016, 37, 111-116.	0.9	13
202	Focal task specific dystonia: a review and update. Journal of Neurology, 2017, 264, 1536-1541.	1.8	79
203	Measuring Disability in Patients With Cervical Dystonia According to the International Classification of Functioning, Disability and Health. OTJR Occupation, Participation and Health, 2017, 37, 132-140.	0.4	10
204	The cognitive features of idiopathic and DYT1 dystonia. Movement Disorders, 2017, 32, 1348-1355.	2.2	23
205	Neuropsychological and Neuropsychiatric Features of Idiopathic and DYT1 Dystonia and the Impact of Medical and Surgical treatment. Archives of Clinical Neuropsychology, 2017, 32, 888-905.	0.3	25
207	Cognitive flexibility in neurological disorders: Cognitive components and event-related potentials. Neuroscience and Biobehavioral Reviews, 2017, 83, 496-507.	2.9	53
208	Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. European Journal of Neurology, 2017, 24, 73-81.	1.7	59
209	Botulinum toxin type A therapy for cervical dystonia. The Cochrane Library, 2017, 12, CD003633.	1.5	92
210	Clinical and Phenomenological Characteristics of Patients with Task-Specific Lingual Dystonia: Possible Association with Occupation. Frontiers in Neurology, 2017, 8, 649.	1.1	29
211	Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 211-229.	0.7	2
212	New Rhizotomy Procedure for Primary Spasmodic Torticollis. Journal of Craniofacial Surgery, 2018, 29, 1338-1340.	0.3	1
213	Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 579-585.	0.9	15
214	Alterations in vestibular function in individuals with cervical dystonia and the effects of botulinum toxin treatment. Basal Ganglia, 2018, 13, 1-6.	0.3	1
215	Pain in focal dystonias – A focused review to address an important component of the disease. Parkinsonism and Related Disorders, 2018, 54, 17-24.	1.1	38
216	Verb naming fluency in hypokinetic and hyperkinetic movement disorders. Cortex, 2018, 100, 21-31.	1.1	9
217	Brueghel Syndrome or Meige Syndrome? Two Sides of a Same Disease. Frontiers of Neurology and Neuroscience, 2018, 41, 98-103.	3.0	4

#	Article	IF	CITATIONS
218	Impaired white matter integrity between premotor cortex and basal ganglia in writer's cramp. Brain and Behavior, 2018, 8, e01111.	1.0	16
219	Dystonia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 229-236.	1.0	6
220	The prevalence of adult-onset isolated dystonia in Finland 2007-2016. PLoS ONE, 2018, 13, e0207729.	1.1	23
221	Epidemiology of benign essential blepharospasm: A nationwide population-based retrospective study in Taiwan. PLoS ONE, 2018, 13, e0209558.	1.1	22
222	Clinical Features of Benign Essential Blepharospasm in Korean Patients. Korean Journal of Ophthalmology: KJO, 2018, 32, 339.	0.5	9
223	Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1119-1124.	1.0	8
224	Epidemiology of Dystonia. , 0, , 27-31.		0
227	Oromandibular Dystonia: Demographics and Clinical Data from 240 Patients. Journal of Movement Disorders, 2018, 11, 78-81.	0.7	29
228	The Impairment of TorsinA's Binding to and Interactions With Its Activator: An Atomistic Molecular Dynamics Study of Primary Dystonia. Frontiers in Molecular Biosciences, 2018, 5, 64.	1.6	20
229	Botulinum Toxin Therapy for Writer's Cramp and Other Focal Hand Dystonias. , 0, , 178-181.		0
230	Dystonia: diagnosis and management. European Journal of Neurology, 2019, 26, 5-17.	1.7	80
231	Range of voluntary neck motility predicts outcome of pallidal DBS for cervical dystonia. Acta Neurochirurgica, 2019, 161, 2491-2498.	0.9	5
232	Validation of a selfâ€completed Dystonia Nonâ€Motor Symptoms Questionnaire. Annals of Clinical and Translational Neurology, 2019, 6, 2054-2065.	1.7	20
233	Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features. Toxins, 2019, 11, 51.	1.5	37
234	The laryngoscope and nineteenth-century British understanding of laryngeal movements. Journal of the Neurosciences, 2019, 28, 262-276.	0.1	0
236	Nationwide prevalence of primary dystonia, progressive ataxia and hereditary spastic paraplegia. Parkinsonism and Related Disorders, 2019, 69, 79-84.	1.1	17
237	The Role of the Neuropsychologist in Deep Brain Stimulation. , 2019, , 185-228.		0
238	Cervical Dystonia Incidence and Diagnostic Delay in a Multiethnic Population. Movement Disorders, 2020, 35, 450-456.	2.2	22

#	Article	IF	Citations
239	Sex differences in movement disorders. Nature Reviews Neurology, 2020, 16, 84-96.	4.9	122
240	Sex differences in movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 175, 275-282.	1.0	7
241	Blepharospasm, dry eye and extractable nuclear antigen antibodies. Journal Francais D'Ophtalmologie, 2020, 43, e211-e215.	0.2	2
242	The efficacy of single-photon emission computed tomography in identifying dystonic muscles in cervical dystonia. Nuclear Medicine Communications, 2020, Publish Ahead of Print, 651-658.	0.5	6
243	Botulinum toxin type A therapy for cervical dystonia. The Cochrane Library, 2020, 2020, CD003633.	1.5	23
245	Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy. Frontiers in Neurology, 2020, 11, 588395.	1.1	10
246	Isolated Cervical Dystonia: Management and Barriers to Care. Frontiers in Neurology, 2020, 11, 591418.	1.1	5
247	Clinical and Demographic Characteristics of Upper Limb Dystonia. Movement Disorders, 2020, 35, 2086-2090.	2.2	9
248	Olfaction as a Marker for Dystonia: Background, Current State and Directions. Brain Sciences, 2020, 10, 727.	1.1	2
250	Predictive factors of outcome in cervical dystonia following deep brain stimulation: an individual patient data meta-analysis. Journal of Neurology, 2020, 267, 1780-1792.	1.8	7
251	Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. Journal of Clinical Movement Disorders, 2020, 7, 2.	2.2	7
252	Smell and taste in cervical dystonia. Journal of Neural Transmission, 2020, 127, 347-354.	1.4	8
253	Focal limb dystonia and tremor: Clinical update. Toxicon, 2020, 176, 10-14.	0.8	3
254	Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins. Toxins, 2020, 12, 269.	1.5	29
255	Emotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia. Journal of Neural Transmission, 2021, 128, 305-314.	1.4	11
256	Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach. Revue Neurologique, 2021, 177, 107-114.	0.6	4
257	The prevalence and clinical features of spasmodic dysphonia: A review of epidemiological surveys conducted in Japan. Auris Nasus Larynx, 2021, 48, 179-184.	0.5	17
259	Case Report: Isolated Lingual Dystonia. F1000Research, 2020, 9, 314.	0.8	0

#	Article	IF	CITATIONS
261	Is Adultâ€Onset Dystonia a Rare Disease? Time for Populationâ€Based Studies. Movement Disorders, 2021, 36, 1119-1124.	2.2	14
262	Blepharospasm, Oromandibular Dystonia, and Meige Syndrome: Clinical and Genetic Update. Frontiers in Neurology, 2021, 12, 630221.	1.1	17
264	Botulinum toxin type A versus anticholinergics for cervical dystonia. The Cochrane Library, 2021, 2021, CD004312.	1.5	1
266	Magnetic Resonanceâ€Guided Focused Ultrasound Thalamotomy for Focal Hand Dystonia: A Pilot Study. Movement Disorders, 2021, 36, 1955-1959.	2.2	20
267	Prevalence and incidence of oromandibular dystonia: an oral and maxillofacial surgery service–based study. Clinical Oral Investigations, 2021, 25, 5755-5764.	1.4	9
268	Smell and taste in idiopathic blepharospasm. Journal of Neural Transmission, 2021, 128, 1215-1224.	1.4	3
269	The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia. Toxins, 2021, 13, 493.	1.5	3
270	The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes. International Journal of Molecular Sciences, 2021, 22, 8100.	1.8	3
271	Second hit hypothesis in dystonia: Dysfunctional cross talk between neuroplasticity and environment?. Neurobiology of Disease, 2021, 159, 105511.	2.1	14
272	Clinical Features and Classification of the Human Dystonias. , 2005, , 227-240.		2
273	DYT1, An Inherited Dystonia. , 2007, , 295-306.		2
274	Dry eye syndrome in benign essential blepharospasm. Journal Francais D'Ophtalmologie, 2019, 42, 1062-1067.	0.2	11
277	Botulinum Toxin Clinic-Based Epidemiologic Survey of Adults with Primary Dystonia in East China. Journal of Movement Disorders, 2012, 5, 9-13.	0.7	2
280	Epidemiology of dystonia. , 2007, , 15-25.		1
281	Genetic Evaluation in Primary Dystonia. Medical Psychiatry, 2006, , 21-44.	0.2	2
282	Epidemiology of dystonia. , 2012, , 11-21.		4
283	Usefulness of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Management of Cervical Dystonia. Annals of Rehabilitation Medicine, 2012, 36, 745.	0.6	10
284	Threshold of Clinical Severity of Cervical Dystonia for Positive18F-FDG PET/CT. Annals of Rehabilitation Medicine, 2013, 37, 777.	0.6	5

	Спинонк	CITATION REPORT	
#	Article	IF	CITATIONS
285	Descriptive epidemiology of cervical dystonia. Tremor and Other Hyperkinetic Movements, 2013, 3, .	1.1	63
286	The Prevalence and Correlation of Non-motor Symptoms in Adult Patients withÂldiopathic Focal or Segmental Dystonia. Tremor and Other Hyperkinetic Movements, 2019, 9, 596.	1.1	23
287	DYT1 Dystonia. , 2003, , 407-418.		1
290	Dystonia: case series of twenty two patients. East African Medical Journal, 2006, 82, 463-7.	0.0	4
291	Limb Dystonia. Medical Psychiatry, 2006, , 155-177.	0.2	0
292	Cranial Dystonia. Medical Psychiatry, 2006, , 121-136.	0.2	0
293	Cervical Dystonia. , 2007, , 591-597.		0
295	Functional imaging in primary dystonia. , 2007, , 57-64.		0
302	Dystonia and Muscle Spindles: The Link in Idiopathic Focal Dystonias. , 0, , .		0
303	Cranial dystonia. , 2012, , 127-143.		0
304	PET and SPECT Imaging in Dystonia. , 2014, , 667-689.		0
305	Long-Term Treatment of Focal Dystonias (Cervical and Writer's Cramp): Clinical and Quality of Life Impact. , 2015, , 151-164.		1
307	How Effective and Safe is Botulinum Toxin Therapy in Cervical Dystonia: The Current Stand. , 0, , .		0
308	THE INFLUENCE OF OCCLUSAL STABILIZATION APPLIANCES ON CERVICAL DYSTONIA SYMPTOMS. Medicine and Pharmacy Reports, 2017, 90, 438-444.	0.2	1
311	Ptosis in Neurologic Disease. , 2021, , 243-278.		0
313	Case Report: Isolated lingual dystonia. F1000Research, 2020, 9, 314.	0.8	2
314	Cervical dystonia: current rehabilitation strategies and methods. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 98-103.	0.2	0
315	Generalized Dystonia Treated With Deep Brain Stimulator: An Institutional Single Surgeon Experience. Cureus, 2020, 12, e10992.	0.2	0

		CITATION REPORT		
#	Article		IF	Citations
316	PET and SPECT Imaging in Dystonia. , 2021, , 799-820.			0
317	Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor and Other Movements, 2014, 4, 273.	r Hyperkinetic	1.1	16
318	Dystonia. Clinical Evidence, 2008, 2008, .		0.2	2
319	Dystonia. Clinical Evidence, 2011, 2011, .		0.2	4
320	Dystonia. Clinical Evidence, 2014, 2014, .		0.2	2
321	Overuse Cervical Dystonia: A Case Report and Literature Review. Tremor and Other Hy Movements, 2016, 6, 413.	perkinetic	1.1	3
322	Involuntary Thumb Flexion on Neurological Examination: An Unusual Form of Upper Lin the Faroe Islands. Tremor and Other Hyperkinetic Movements, 2019, 9, .	nb Dystonia in	1.1	2
323	Dystonias. , 2021, , .			0
324	Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysp Toxins, 2021, 13, 840.	vhonia in Japan.	1.5	8
325	Risk factors for the development of degenerative cervical myelopathy: a review of the Neurosurgical Review, 2022, 45, 1675-1689.	iterature.	1.2	18
326	Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin Aâ€' Experience in a Tertiary Care Center. Toxins, 2022, 14, 120.	'30 Years of	1.5	3
327	Hold that pose: capturing cervical dystonia's head deviation severity from video. Annal and Translational Neurology, 2022, 9, 684-694.	s of Clinical	1.7	9
328	Diagnostic Neurophysiologic Biomarkers for <scp>Task‧pecific</scp> Dystonia. Mo Clinical Practice, 2022, 9, 468-472.	vement Disorders	0.8	1
332	Tremor in Writer's Cramp Patients: A Retrospective Study. , 0, 1, .			0
333	Oromandibular dystonia seen during pramipexole treatment: A rare case. Journal of Su Medicine, 2022, 6, 1-1.	rgery and	0.0	0
334	OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Dystonia: A Cohort Analysis From CD PROBE. Frontiers in Neurology, 0, 13, .	Cervical	1.1	4
335	Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Updat 451.	e. Toxins, 2022, 14,	1.5	5
336	Movement disorders of the mouth: a review of the common phenomenologies. Journal 2022, 269, 5812-5830.	of Neurology,	1.8	5

ARTICLE IF CITATIONS # Bilateral pallidotomy for acquired or heredodegenerative generalized dystonia in children. 337 1.0 1 Neurosurgical Focus, 2022, 53, E12. Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp. Movement 2.2 Disorders, 2023, 38, 123-132. Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with 339 1.5 2 Blepharospasm and Hemifacial Spasm on Antithrombotic Medication. Toxins, 2022, 14, 769. Role of Cerebellum in the Treatment of Dystonia and Application of Cerebellum Transcranial Magnetic 340 0.1 Stimulation. Rehabilitation Medicine, 2022, 32, 279-284. Oromandibular Dystonia: Clinical and Demographic Data from Eight-Two Patients. Tremor and Other 341 1.1 1 Hyperkinetic Movements, 2023, 13, . A Systematic Review of Cognition in Cervical Dystonia. Neuropsychology Review, 2024, 34, 134-154. 2.5 Altered brain state during episodic dystonia in tottering mice decouples primary motor cortex from 344 0 limb kinematics., 0, 2, . Research Progress of Botulinum Toxin Type A in the Treatment of Benign Essential Blepharospasm. Advances in Clinical Medicine, 2023, 13, 3626-3630. Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center 346 1.1 0 observational study. PLoS ONE, 2023, 18, e0283111. Early-onset inherited dystonias versus late-onset idiopathic dystonias: Same or different biological mechanisms?. International Review of Neurobiology, 2023, , 329-346. Neurosurgical management of non-spastic movement disorders. Child's Nervous System, 2023, 39, 352 0.6 1 2887-2898. Isolated and combined dystonias: Update. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 425-442. BK 2115 – Fokale Dystonie als Erkrankung des zentralen Nervensystems bei Instrumentalmusikern 363 0.0 0 durch feinmotorische TAugkeit hoher IntensitAu Springer Reference Medizin, 2024, , 1-4.